Disclaimer to the online edition
This Manual has been designed for use in the NICU at London Health Sciences Centre (LHSC), London, Ontario, Canada, and represents clinical practice at this institution. The information contained within the Manual may not be applicable to other centres. If users of this Manual are not familiar with a drug, it is recommended that the official monograph be consulted before it is prescribed and administered. Any user of this information is advised that the contributors, Editor and LHSC are not responsible for any errors or omissions, and / or any consequences arising from the use of the information in this Manual.
amikacin
Indication
- An aminoglycoside antibiotic used to treat serious infections caused by organisms resistant to gentamicin and tobramycin including Pseudomonas, Klebsiella, Enterobacter, Serratia, Proteus and E. coli
Dosage Guidelines
Postnatal Age | Weight (kg) | Dose |
|---|---|---|
All | Less than 1.2 | 7.5 mg/kg/dose IV/IM q24 hours |
0 to 7 days | 1.2 to 2 | 7.5 mg/kg/dose IV/IM q12 hours |
Greater than 2 | 10 mg/kg/dose IV/IM q12 hours | |
Greater than 7 days | 1.2 to 2 | 6.7 mg/kg/dose IV/IM q8 hours |
Greater than 2 | 10 mg/kg/dose IV/IM q8 hours |
Administration
- IV intermittent slow infusion over 30 minutes
- To make 10 mL of a 5 mg/mL solution:
1. Draw up 0.2 mL of the 250 mg/mL solution
2. Add to 9.8 mL D5W to make a total volume of 10 mL
- IM (if no IV available)
Adverse Effects
- Ototoxicity and nephrotoxicity
Comments
- Monitor urine output.
- Administration with furosemide and vancomycin may cause additive oto/nephrotoxicity
- Prolong dosing interval in renal impairment
- Neuromuscular blockage and respiratory failure may be compounded if treating with rocuronium or other muscular blocking agents
- If treatment is planned for more than 48 hours, draw serum levels pre and post the 3rd dose. Draw the pre-level (trough) just prior to administering the dose. Draw the post-level (peak) 30 minutes after the infusion is finished
- Target trough concentration is less than 10 mg/L and target peak concentration is between 20-35 mg/L depending on indication
Supplied As
- 5 mg/mL patient specific syringe, prepared by Pharmacy